Alitair Presents at National Investment Banking Association Meeting in New York City (Click for Video)

Alitair Pharmaceuticals CEO, James Hoyes, presents the corporate overview and strategic direction during the National Investment Banking Association (NIBA) Meeting in NYC. The meeting ran February 27-28, 2017.

Mr. Hoyes focused on the proprietary ion-exchange resin formulation technology that supports the highly innovative Overdose Reduction technology and forms the basis of its non-narcotic and narcotic prescription cough medicines portfolio. The Overdose Reduction technology, called ODR, may serve as a significant product in the fight against the Opioid Crisis. ODR serves to minimize the risk of overdose due to the abuse and/or misuse of prescription medicines especially opioids and benzodiazepines. Mr. Hoyes also reviewed the portfolio of Orphan Drugs focused on the rare pulmonary disease called bronchiectasis.

Alitair Pharmaceuticals